MADRIGAL PHARMACEUTICALS, INC. (MDGL) Return on equity 2017–2025
MADRIGAL PHARMACEUTICALS, INC. (MDGL) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-47.8%FY2025 · since FY2017: -17.1% → -47.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -47.8% | +13.9 pp |
| FY2024 | -61.8% | +30.4 pp |
| FY2023 | -92.2% | +57.4 pp |
| FY2022 | -149.6% | -26.3 pp |
| FY2021 | -123.3% | -39.0 pp |
| FY2020 | -84.3% | -64.1 pp |
| FY2019 | -20.2% | -13.3 pp |
| FY2018 | -6.9% | +10.2 pp |
| FY2017 | -17.1% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice